Cargando…

A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis

AIMS: To identify linzagolix doses, an oral GnRH receptor antagonist, that effectively lower oestradiol (E2) to relieve endometriosis‐related pelvic pain without compromising bone health. METHODS: Integrated statistical, pharmacokinetic–pharmacodynamic and systems pharmacology models were developed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pohl, Oliver, Baron, Kyle, Riggs, Matthew, French, Jonathan, Garcia, Ramon, Gotteland, Jean‐Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306723/ https://www.ncbi.nlm.nih.gov/pubmed/34904270 http://dx.doi.org/10.1111/bcp.15171

Ejemplares similares

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?
por: Rzewuska, Anna Maria, et al.
Publicado: (2023)

Gonadotropin-Releasing Hormone (GnRH)/GnRH Receptors and Their Role in the Treatment of Endometriosis
por: Resta, Christina, et al.
Publicado: (2023)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist
por: Polepally, Akshanth R., et al.
Publicado: (2020)

Small molecule piperazinyl-benzimidazole antagonists of the gonadotropin-releasing hormone (GnRH) receptor
por: Fjellaksel, Richard, et al.
Publicado: (2017)

Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer
por: Liu, Yi-Fu, et al.
Publicado: (2021)

Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cycles
por: Jain, Shikha, et al.
Publicado: (2016)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
por: Osuga, Yutaka, et al.
Publicado: (2021)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Discovery of a Lead Brain‐Penetrating Gonadotropin‐Releasing Hormone Receptor Antagonist with Saturable Binding in Brain
por: Bekker, Roberto B. W., et al.
Publicado: (2020)

Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis
por: Xin, Lingli, et al.
Publicado: (2023)

Editorial: Gonadotropin-Releasing Hormone Receptor Signaling and Functions
por: Bjelobaba, Ivana, et al.
Publicado: (2018)

Apoptotic Death of Prostate Cancer Cells by a Gonadotropin-Releasing Hormone-II Antagonist
por: Park, Sumi, et al.
Publicado: (2014)

The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome
por: Chappell, Neil, et al.
Publicado: (2017)

The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles
por: Komiya, Shinnosuke, et al.
Publicado: (2022)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

Invertebrate Gonadotropin-Releasing Hormone-Related Peptides and Their Receptors: An Update
por: Sakai, Tsubasa, et al.
Publicado: (2017)

Gonadotropin-Releasing Hormone Receptor (GnRHR) and Hypogonadotropic Hypogonadism
por: Fanis, Pavlos, et al.
Publicado: (2023)

Early gonadotropin-releasing hormone antagonist start improves follicular synchronization and pregnancy outcome as compared to the conventional antagonist protocol
por: Park, Chan Woo, et al.
Publicado: (2014)

Luteal estradiol supplementation in gonadotropin-releasing hormone antagonist cycles for infertile patients in vitro fertilization
por: Kwon, Su-Kyoung, et al.
Publicado: (2013)

Comparative proteomics reveal negative effects of gonadotropin-releasing hormone agonist and antagonist on human endometrium
por: Chen, Qian, et al.
Publicado: (2019)

Editorial Comment to Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer
por: Kawahara, Takashi
Publicado: (2020)

Pretreatment with gonadotropin-releasing hormone antagonist protects against chemotherapy-induced testicular damage ‘in mice
por: Levi, Mattan, et al.
Publicado: (2022)

Development of the gonadotropin‐releasing hormone system
por: Duittoz, Anne H., et al.
Publicado: (2022)

Comparative multiplex analysis of cytokines, chemokines and growth factors in follicular fluid of normoresponder women undergoing ovum donation with gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist protocols
por: Malhotra, Neena, et al.
Publicado: (2013)

Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis
por: Lee, Dong-Yun, et al.
Publicado: (2016)

Rapidly growing extensive polypoid endometriosis after gonadotropin-releasing hormone agonist discontinuation: A case report
por: Zhang, De-Yu, et al.
Publicado: (2023)

Hormonal induction of spawning in 4 species of frogs by coinjection with a gonadotropin-releasing hormone agonist and a dopamine antagonist
por: Trudeau, Vance L, et al.
Publicado: (2010)

Luteinizing hormone changes in gonadotropin-releasing hormone antagonist protocol in in vitro fertilization cycles: A cross-sectional study
por: Hosein Rashidi, Batool, et al.
Publicado: (2019)

Diminished Ovarian Reserve Predisposes to Premature Luteinizing Hormone Surges in Gonadotropin-Releasing Hormone Antagonist Cycles in In vitro Fertilization
por: Kochhar, Puneet Kaur, et al.
Publicado: (2020)

Differential Effects of Oxytocin Receptor Antagonists, Atosiban and Nolasiban, on Oxytocin Receptor–Mediated Signaling in Human Amnion and Myometrium
por: Kim, Sung Hye, et al.
Publicado: (2017)

Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF
por: Nakao, Kazuki, et al.
Publicado: (2021)

AXL receptor tyrosine kinase modulates gonadotropin-releasing hormone receptor signaling
por: Mohammadzadeh, Pardis, et al.
Publicado: (2023)

Comparison of Two Regimens of Gonadotropin-releasing Hormone Antagonists in Clomiphene-gonadotropin Induced Controlled Ovulation and Intrauterine Insemination Cycles: Randomized Controlled Study
por: Karthik, Sajja Devendra Siva, et al.
Publicado: (2018)

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol
por: Chang, Hye Jin, et al.
Publicado: (2009)

The effect of luteal phase gonadotropin-releasing hormone antagonist administration on IVF outcomes in women at risk of OHSS
por: Eftekhar, Maryam, et al.
Publicado: (2016)

A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pmq7mnocif0tng6t3objvugbat